x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

37:29

125. Spotlight - Biotech ImmVirX with Dr Malcolm...

Oncology for the Inquisitive Mind ·

2024/08/17

Oncolytic viruses thrive in cancer cells and can replicate rapidly, destroying the cells and enabling the immune system to attack tumours. This week, we interview Dr Malcolm McColl and Prof Darren Shafren, a dynamic duo in Australian biotechnology and part of the leadership team of ImmVirx, a viral oncolytic company. Prior to creating ImmVirx, they successfully launched the product Cavatak, used in melanoma and other malignancies.ImmVirx has developed a proprietary bio-selected RNA virus that is

en

30:40

124. Metastatic HER2- positive breast cancer

Oncology for the Inquisitive Mind ·

2024/08/10

Metastatic HER2-positive breast cancer continues to dominate headlines, and new therapeutic options continue to be found for those afflicted with the disease. Before trastuzumab (anti-HER2 therapy), the overall survival for this cohort of patients was less than two years. As technology and treatments changed, it can boast an extended survival well beyond five years in numerous studies, with many patients responding far more than that number.This week, we will discuss two exciting and pioneering

en

25:51

123. Spotlight: MARIPOSA for EGFRmut Lung Cancer

Oncology for the Inquisitive Mind ·

2024/08/03

The discovery of EGFR as a driver mutation and the development of medications to take advantage of this mutation changed the treatment of non-small cell lung cancer (NSCLC) forever. Not only did it vastly improve outcomes for patients with this subset of cancers, it opened the door for the likes of alectinib, lorlatinib and sotorasib to carve out niches for their own driver mutations. However, the treatment remains imperfect and people much smarter than Josh and Michael have been hard at work trying

en

43:59

122. Palliative Care with Dr Janet Abrahm

Oncology for the Inquisitive Mind ·

2024/07/27

It is rare on any show to be able to interview a true pioneer. On today's episode of Oncology for the Inquisitive Mind, we have the privilege of interviewing Dr Janet Abrahm, a pioneer in every sense of the word. An internist with over 20 years experience, Dr Abrahm was one of the founders and earliest proponents of palliative care in the United States. A staff specialist at the Dana Farber Cancer Institute, she is board-certified in Hematology, Hospice and Palliative Medicine, Internal Medicine,

en

36:04

121. Dr Elias Chandran, the NCI and urothelial...

Oncology for the Inquisitive Mind ·

2024/07/20

This week, we interview Dr Elias Chandran, a medical oncologist and emerging research juggernaut who is an assistant research physician at the National Cancer Institute in Bethesda, Maryland. His focus is on genitourinary cancer, and he has recently published a pivotal systematic review and meta-analysis titled "Mismatch repair deficiency and microsatellite instability-high in urothelial carcinoma: A systematic review and meta-analysis".Dr Chandran is the epitome of a resilient clinician, having

en

42:11

137. Artificial Intelligence with Professor Meredith...

Oncology for the Inquisitive Mind ·

2024/07/13

Today, Michael and Josh interview Professor Meredith Broussard, author of More than a Glitch and data journalist at the Arthur L Carter Journalism Institute of New York University. Meredith has had an exceptionally versatile career, previously having worked as a software developer for MIT Media Lab and a former features editor at the Philadelphia Inquirer. She is also the author of numerous other books, including Confronting Race, Gender, and Ability Bias in Tech” and “Artificial Unintelligence. She

en

52:17

119. ASCO 2024 - Plenary Session

Oncology for the Inquisitive Mind ·

2024/06/17

"Here at last, at the edge of the sea, comes the end of our Fellowship." So said Gandalf the White at the conclusion of J.R.R Tolkien's epic The Lord of the Rings. Today, Josh and Michael have a no less epic conclusion to their own adventure, that of ASCO 2024. Over the last fifteen days, our intrepid hosts have journeyed across the world of medical oncology, from the highs of colorectal, breast and lung cancer to the dark days of central nervous system tumours. As is our tradition, we end our

en

19:51

118. ASCO 2024 - Sarcoma

Oncology for the Inquisitive Mind ·

2024/06/16

Today is the penultimate episode in our ASCO 2024 Odyssey. Michael and Josh have neglected sarcoma to date, but today is the day@ Sarcoma is rare, where clinician experience becomes paramount to treatment options and outcomes. They develop in soft tissues and bones and vary in origin, including deep soft tissue, bone, nerves, etc. Today, they explore three trials. The first is paclitaxel and avelumab in inoperable angiosarcoma, the second is perioperative radiotherapy with adjuvant immunotherapy in

en

25:27

117. ASCO 2024 - Central Nervous System

Oncology for the Inquisitive Mind ·

2024/06/15

Some consider the number 13 unlucky; fear of the number has its own name, "triskaidekaphobia." So it is perhaps somewhat fitting that day 13 of our ASCO Odyssey is dedicated to the cancer type with which scientists and doctors have had arguably the least luck in treating: central nervous system cancers. We still await CNS oncology's immunotherapy or EGFR/ALK moment, and unfortunately, as of ASCO 2024, that has not come yet. However, that has not stopped legions of incredibly dedicated and

en

28:06

116. ASCO 2024 - Early Lung Cancer & Mesothelioma

Oncology for the Inquisitive Mind ·

2024/06/14

ASCO 2024 beat many attendees' expectations with interesting and thought-provoking lung cancer and mesothelioma studies. While not all of these will change the face of patient treatment, they will add to a body of evidence for biomarkers and build on the blocks of tailoring treatment to patients.Links to studies discussed in this episode (subscription may be required):BEAT-meso: Link Checkmate 816 4 year update: LinkMIST5: LinkctDNA-Lung-DETECT: Link BEAT-SC: Link For more episodes, resources and

en

25:41

115. ASCO 2024 - Head and Neck Cancer

Oncology for the Inquisitive Mind ·

2024/06/13

Our coverage of ASCO 2024 has rounded the final bend, and the finish line is in sight. Today, Josh and Michael examine four studies in the head and neck cancer space. Today's studies include a novel, viral-driven vector that aims to increase the immune response to treatment, potential treatment for the very rare nasal squamous cell cancer, data supporting the treatment of patients with poor prognosis and head and neck patients, and a new, intensive immunotherapy treatment for nasopharyngeal cancer

en

23:50

114. ASCO 2024 - Early Colorectal Cancer

Oncology for the Inquisitive Mind ·

2024/06/12

ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many other rectal cancer trials and a spattering of neoadjuvant colorectal trials, the ability to redefine and provide clarity to this area is pertinent. Today, it heavily focuses on immunotherapy in the colon space with sintilimab and IBI310 battling it out with the old master pembrolizumab. The rectal

en

22:48

113. ASCO 2024 - Metastatic Colorectal Cancer

Oncology for the Inquisitive Mind ·

2024/06/11

Our 2024 ASCO epic trundles onto its next generation, advanced colorectal cancer. Over the last 10 years, treatment in this area has made incremental progress through the discovery of the clinically meaningful KRAS and BRAF mutation pathways and most recently with the potential for immunotherapy in the deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) subgroups. In this episode, Josh and Michael examine studies looking at KRAS G12C-mutated, HER2-positive and dMMR

en

29:05

112. ASCO 2024 - Upper Gastrointestinal and...

Oncology for the Inquisitive Mind ·

2024/06/10

Some oncologists may have already started counting down to ASCO 2025. However, Michael and Josh are still digesting the interesting world of ASCO 2024, specifically upper GI and Hepatobiliary Cancers and, like Aladdin, explicitly referring to the Disney 1992 cult classic featuring Robbin Williams, here to lie several diamonds in the rough.We cover perioperative FLOT in the metastatic setting, but most excitingly, it is a potentially new groundbreaking treatment for hepatocellular carcinoma.Links to

en

26:33

111. ASCO 2024 - Genitourinary Cancers (Prostate/Penile)

Oncology for the Inquisitive Mind ·

2024/06/09

The second of our two GU ASCO 2024 episodes focusses on prostate and penile cancer, two diseases at different ends of the therapeutic spectrum. Prostate cancer is one of the most common cancers in men, with well established, nuanced treatment paradigms and a glut of high-quality evidence. Penile SCC is a very rare cancer that tragically is much more common in low socioeconomic countries. Treatment options are as limited as available evidence, so any new studies of this cancer are very welcome. Are

en

26:44

110. ASCO 2024 - Genitourinary Cancers (Bladder/Kidney)

Oncology for the Inquisitive Mind ·

2024/06/08

Genitourinary Cancers dominated ASCO24 this year, and Josh and Michael's ASCO Odyssey needed two episodes to fit it all in. Join them as they board the Nautilus with Captain Nemo in search of the best trials to propel bladder and renal cancer to the forefront of your mind. This episode covers both the use of perioperative sacituzumab govitecan, avelumab as neoadjuvant therapy for bladder cancer and camrelizumab for previously treated advanced adrenocortical carcinoma. Not to be forgotten, they

en

37:43

109. ASCO 2024 - Early Breast Cancer

Oncology for the Inquisitive Mind ·

2024/06/07

Unbeknownst to Josh, we are already at Day 5 of our ASCO Odyssey, and like Odysseus arriving at Circe's island of Aeaea, we have arrived at the episode devoted to early Breast Cancer. Today we examine four very interesting studies, looking at alternative immunotherapy strategies with adjuvant avelumab, adjuvant endocrine therapy omission in low-ER positive disease, ctDNA in predicting disease recurrence, and a study that aims to change the very bedrock of breast cancer classification. Lots to

en

34:57

108. ASCO 2024 - Metastatic Brest Cancer

Oncology for the Inquisitive Mind ·

2024/06/06

Today, Michael and Josh approach a singular destiny to present their take on Metastatic Breast Cancer at ASCO 2024. Long has Breast Cancer been one of the most diagnosed cancers globally; these days, it leads the herd with effective treatment options and paradigm shifts that benefit millions of people on a massive scale. With CDK4/6 inhibitors, immunotherapy and antibody-drug conjugates, the arsenal of effective treatment tools continues to grow! Nothing excites an oncologist more than a good

en

33:47

107. ASCO 2024 - Gynaecological Cancer

Oncology for the Inquisitive Mind ·

2024/06/05

Day 3 of Oncology for the Inquisitive Mind's ASCO Odyssey and our hosts show no sign of flagging under this immense pressure, although Josh has started to give up on his famous segues. In this episode, our intrepid hosts tackle gynaecological cancers, reporting on four of their favourite studies from a packed field of gynaecological cancers. Will new treatment options for cervical cancer emerge? Will the sugical approach to recurrent ovarian cancer change? Is there still a place for single agent

en

31:26

106. ASCO 2024 - Melanoma

Oncology for the Inquisitive Mind ·

2024/06/04

As the sun rises on another day at ASCO, Michael and Josh are ready to hit the ground running to bring you the latest and greatest in all things oncology in Chicago has to offer. No greek mythology today, only a burning desire to bring you the biggest melanoma trials from ASCO24. Today, they pack a punch, tackling some intriguing phase 1 trials with tongue-twisting names where the novelty wears off pretty quickly!Links to articles discussed in this episode (subscription may be required):

en

202 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown